作者:Cheng Zhu、Liping Wang、Yuping Zhu、Zack Zhiqiang Guo、Ping Liu、Zhiyong Hu、Jason W. Szewczyk、Ling Kang、Gary Chicchi、Anka Ehrhardt、Andrea Woods、Toru Seo、Morgan Woods、Margaret van Heek、Karen H. Dingley、Jianmei Pang、Gino M. Salituro、Joyce Powell、Jenna L. Terebetski、Viktor Hornak、Louis-Charles Campeau、Robert K. Orr、Feroze Ujjainwalla、Michael Miller、Andrew Stamford、Harold B. Wood、Timothy Kowalski、Ravi P. Nargund、Scott D. Edmondson
DOI:10.1016/j.bmcl.2017.01.091
日期:2017.3
The paper describes the SAR/SPR studies that led to the discovery of phenoxy cyclopropyl phenyl acetamide derivatives as potent and selective GPR119 agonists. Based on a cis cyclopropane scaffold discovered previously, phenyl acetamides such as compound 17 were found to have excellent GPR119 potency and improved physicochemical properties. Pharmacokinetic data of compound 17 in rat, dog and rhesus
本文介绍了SAR / SPR研究,该研究导致发现了作为有效和选择性GPR119激动剂的苯氧基环丙基苯基乙酰胺衍生物。基于先前发现的顺式环丙烷支架,发现苯基乙酰胺(如化合物17)具有出色的GPR119效能和改善的理化特性。将描述化合物17在大鼠,狗和恒河猴中的药代动力学数据。基于化合物17的预期人类半衰期,其化合物适合QD给药,其人体预测剂量远低于最近报道的与结构相关的苄氧基化合物2的剂量。化合物17 被选为NHP(非人类灵长类动物)功效研究的工具化合物候选者。